OTC Device Claims For COPD ‘Therapy’ Put Patients At Risk – UK Regulator
This article was originally published in The Pink Sheet
Executive Summary
ASA finds device marketer BioLife Solutions could not rely on a disclaimer and use of the word “therapy” instead of “treatment” to offset the message its Airnergy device treats a medical condition. ASA advices not to make COPD treatment claims unless a product is properly certified.
You may also be interested in...
UK Homeopathic Energy 'Balance' Claims Tilt Consumers Toward Trouble
UK regulator tells Natural Healing Solutions to discontinue online claims its products are “programmed” with resonance patterns to read energy levels and prevent disease. In a ruling published April 19, the agency noted the company acknowledged receipt of the complaint, but did not respond.
Industry Roundup: DXM Bill Moves, CHPA Biz Dev VP, Neurobrands Injunction
House subcommittee approves DXM Abuse bill; UK ire for US firm’s patch claims; Innophos VP hire; and more news in brief.
IFF Narrows Focus To Fragrance, Health, Food
International Flavors & Fragrances agrees to sell its Pharma Solutions business to plant-based ingredients company Roquette for an enterprise value of $2.85bn to reduce debt and streamline its business to three segments, including scents.